Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Pyridoxal Phosphate

What is Pyridoxal Phosphate?

CAS No: 54-47-7

Pyridoxal Phosphate is the salt form of its parent API, engineered to achieve a target aqueous solubility and dissolution profile that ensures consistent oral bioavailability across the patient population. The stoichiometry of API to counter-ion, defined in the salt’s molecular formula, determines the dose equivalent and the appropriate molecular weight correction applied when converting the PDE value to a cleaning validation maximum allowable carryover expressed in mass of salt per unit equipment surface area or per unit rinse volume.

The pharmacologically-based OEL approach is used for Pyridoxal Phosphate when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies. The pharmacodynamic NOAEL established from clinical pharmacology studies—typically from the lowest dose producing a measurable but non-adverse pharmacological effect in healthy volunteers—is divided by the intraspecie

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Pyridoxal Phosphate is the active coenzyme form associated with vitamin B6 metabolism. Its chemical and biological role provides context, while any exposure assessment should rely on relevant evidence for the material and intended use. Understanding the evidence and conditions of use helps support a documented, risk-based approach to handling.

A PDE or ADE sets a health-based limit on daily exposure to Pyridoxal Phosphate from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

An occupational exposure band can help categorize a substance and guide proportionate containment and handling controls. It does not automatically replace a substance-specific occupational exposure limit. Whether an OEL is available and how the band is assigned depend on the evidence and the framework used. The report should clearly distinguish the purpose and limitations of each.

The physical form and handling conditions of Pyridoxal Phosphate can influence how exposure may occur. For example, powder handling may create different inhalation considerations from transferring a solution, while process steps and containment also matter. The occupational assessment should use the available information about the material and actual tasks rather than assume that one form represents every scenario.

Published toxicity data can be limited for some substances. The assessment can consider the quality of available evidence, relevant information from related compounds, and scientifically justified structure-based approaches where appropriate. Any read-across, assumptions, and uncertainty should be clearly documented. The strength of the conclusion must remain proportionate to the evidence and its limitations.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Pyridoxal Phosphate in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Therapeutic dose information may provide context when assessing a marketed active substance, but it is not sufficient on its own to establish a PDE, ADE, or OEL. The assessment must evaluate the relevant toxicological endpoints, route, population, and quality of evidence. Any use of dose information should be scientifically justified and clearly distinguished from the final exposure-limit derivation.

The assessment considers how Pyridoxal Phosphate may be handled during relevant activities such as dispensing, charging, transfer, sampling, equipment maintenance, and cleaning. Exposure potential depends on the process, material form, containment, and work practices. Considering the actual tasks helps connect the toxicological evaluation with practical controls and identifies where additional exposure information may be useful.

Formulation and cleaning steps can involve different handling conditions and potential exposure pathways for Pyridoxal Phosphate. The assessment should consider the material form, process design, containment, and tasks performed, using available evidence to characterize plausible exposure. These details help determine whether additional controls or route-specific evaluation may be needed, while keeping conclusions tied to the actual manufacturing context.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Pyridoxal Phosphate to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo